Top

04-10-2016 | Systemic lupus erythematosus | Book Chapter | Article

4. Systemic Lupus Erythematosus: Clinical Aspects

Authors: Savino Sciascia, Maria Josè Cuadrado

Publisher: Springer International Publishing

Abstract

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disorder that results from a combination of genetic, environmental, and hormonal factors. The disease is characterized by a heterogeneous clinical presentation, a different course in different individuals, and a variability in the disease progression/fluctuations within the same patient. The clinical picture of SLE is extremely variable and may be related to disease activity, organ damage, drug toxicity, and quality of life.

Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C et al (2008) EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 67(2):195–205CrossRefPubMed

Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Brey R et al (2010) European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 69(7):1269–1274CrossRefPubMedPubMedCentral

Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR et al (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64(8):2677–2686CrossRefPubMedPubMedCentral

Zonana-Nacach A, Roseman JM, McGwin G Jr, Friedman AW, Baethge BA, Reveille JD et al (2000) Systemic lupus erythematosus in three ethnic groups. VI: factors associated with fatigue within 5 years of criteria diagnosis. LUMINA Study Group. LUpus in MInority populations: NAture vs nurture. Lupus 9(2):101–109CrossRefPubMed

Pettersson S, Lovgren M, Eriksson LE, Moberg C, Svenungsson E, Gunnarsson I et al (2012) An exploration of patient-reported symptoms in systemic lupus erythematosus and the relationship to health-related quality of life. Scand J Rheumatol 41(5):383–390CrossRefPubMed

Burgos PI, Alarcon GS, McGwin G Jr, Crews KQ, Reveille JD, Vila LM (2009) Disease activity and damage are not associated with increased levels of fatigue in systemic lupus erythematosus patients from a multiethnic cohort: LXVII. Arthritis Rheum 61(9):1179–1186CrossRefPubMedPubMedCentral

Jump RL, Robinson ME, Armstrong AE, Barnes EV, Kilbourn KM, Richards HB (2005) Fatigue in systemic lupus erythematosus: contributions of disease activity, pain, depression, and perceived social support. J Rheumatol 32(9):1699–1705PubMed

Tench CM, McCarthy J, McCurdie I, White PD, D’Cruz DP (2003) Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise. Rheumatology 42(9):1050–1054CrossRefPubMed

Buskila D, Press J, Abu-Shakra M (2003) Fibromyalgia in systemic lupus erythematosus: prevalence and clinical implications. Clin Rev Allergy Immunol 25(1):25–28CrossRefPubMed

10.

Torrente-Segarra V, Carbonell-Abello J, Castro-Oreiro S, Manresa Dominguez JM (2010) Association between fibromyalgia and psychiatric disorders in systemic lupus erythematosus. Clin Exp Rheumatol 28(6 Suppl 63):S22–S26PubMed

11.

Friedman AW, Tewi MB, Ahn C, McGwin G Jr, Fessler BJ, Bastian HM et al (2003) Systemic lupus erythematosus in three ethnic groups: XV. Prevalence and correlates of fibromyalgia. Lupus 12(4):274–279CrossRefPubMed

12.

Bachen EA, Chesney MA, Criswell LA (2009) Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus. Arthritis Rheum 61(6):822–829CrossRefPubMedPubMedCentral

13.

Meszaros ZS, Perl A, Faraone SV (2012) Psychiatric symptoms in systemic lupus erythematosus: a systematic review. J Clin Psychiatry 73(7):993–1001CrossRefPubMed

14.

Petri M, Naqibuddin M, Carson KA, Wallace DJ, Weisman MH, Holliday SL et al (2010) Depression and cognitive impairment in newly diagnosed systemic lupus erythematosus. J Rheumatol 37(10):2032–2038CrossRefPubMed

15.

Choi ST, Kang JI, Park IH, Lee YW, Song JS, Park YB et al (2012) Subscale analysis of quality of life in patients with systemic lupus erythematosus: association with depression, fatigue, disease activity and damage. Clin Exp Rheumatol 30(5):665–672PubMed

16.

Moldovan I, Katsaros E, Carr FN, Cooray D, Torralba K, Shinada S et al (2011) The Patient Reported Outcomes in Lupus (PATROL) study: role of depression in health-related quality of life in a Southern California lupus cohort. Lupus 20(12):1285–1292CrossRefPubMed

17.

Lapteva L, Nowak M, Yarboro CH, Takada K, Roebuck-Spencer T, Weickert T et al (2006) Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum 54(8):2505–2514CrossRefPubMed

18.

Giovacchini G, Mosca M, Manca G, Della Porta M, Neri C, Bombardieri S et al (2010) Cerebral blood flow in depressed patients with systemic lupus erythematosus. J Rheumatol 37(9):1844–1851CrossRefPubMed

19.

Newman K, Owlia MB, El-Hemaidi I, Akhtari M (2013) Management of immune cytopenias in patients with systemic lupus erythematosus – old and new. Autoimmun Rev 12(7):784–791CrossRefPubMed

20.

Fayyaz A, Igoe A, Kurien BT, Danda D, James JA, Stafford HA et al (2015) Haematological manifestations of lupus. Lupus Sci Med 2(1):e000078CrossRefPubMedPubMedCentral

21.

Rivero SJ, Diaz-Jouanen E, Alarcon-Segovia D (1978) Lymphopenia in systemic lupus erythematosus. Clinical, diagnostic, and prognostic significance. Arthritis Rheum 21(3):295–305CrossRefPubMed

22.

Harvey AM, Shulman LE, Tumulty PA, Conley CL, Schoenrich EH (1954) Systemic lupus erythematosus: review of the literature and clinical analysis of 138 cases. Medicine 33(4):291–437CrossRefPubMed

23.

Arenas M, Abad A, Valverde V, Ferriz P, Pascual R (1992) Selective inhibition of granulopoiesis with severe neutropenia in systemic lupus erythematosus. Arthritis Rheum 35(8):979–980CrossRefPubMed

24.

Haddy TB, Rana SR, Castro O (1999) Benign ethnic neutropenia: what is a normal absolute neutrophil count? J Lab Clin Med 133(1):15–22CrossRefPubMed

25.

He J, Guo JP, Ding Y, Li YN, Pan SS, Liu Y et al (2011) Diagnostic significance of measuring antibodies to cyclic type 3 muscarinic acetylcholine receptor peptides in primary Sjogren’s syndrome. Rheumatology 50(5):879–884CrossRefPubMed

26.

Kuwana M, Kaburaki J, Okazaki Y, Miyazaki H, Ikeda Y (2006) Two types of autoantibody-mediated thrombocytopenia in patients with systemic lupus erythematosus. Rheumatology 45(7):851–854CrossRefPubMed

27.

Lurie DP, Kahaleh MB (1982) Pulse corticosteroid therapy for refractory thrombocytopenia in systemic lupus erythematosus. J Rheumatol 9(2):311–314PubMed

28.

Tincani A, Biasini-Rebaioli C, Cattaneo R, Riboldi P (2005) Nonorgan specific autoantibodies and heart damage. Lupus 14(9):656–659CrossRefPubMed

29.

Sarzi-Puttini P, Atzeni F, Gerli R, Bartoloni E, Doria A, Barskova T et al (2010) Cardiac involvement in systemic rheumatic diseases: an update. Autoimmun Rev 9(12):849–852CrossRefPubMed

30.

Brigden W, Bywaters EG, Lessof MH, Ross IP (1960) The heart in systemic lupus erythematosus. Br Heart J 22:1–16CrossRefPubMedPubMedCentral

31.

Kao AH, Manzi S (2002) How to manage patients with cardiopulmonary disease? Best Pract Res Clin Rheumatol 16(2):211–227CrossRefPubMed

32.

Godeau P, Guillevin L, Fechner J, Herreman G, Wechsler B (1981) Cardiac involvement in systemic lupus erythematosus. 103 cases (author’s transl). Nouv Press Med 10(26):2175–2178

33.

Tincani A, Rebaioli CB, Taglietti M, Shoenfeld Y (2006) Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus. Rheumatology 45(Suppl 4):iv8–iv13PubMed

34.

Sherer Y, Levy Y, Shoenfeld Y (1999) Marked improvement of severe cardiac dysfunction after one course of intravenous immunoglobulin in a patient with systemic lupus erythematosus. Clin Rheumatol 18(3):238–240CrossRefPubMed

35.

Alessandri C, Conti F, Pendolino M, Mancini R, Valesini G (2011) New autoantigens in the antiphospholipid syndrome. Autoimmun Rev 10(10):609–616CrossRefPubMed

36.

Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost: JTH 4(2):295–306CrossRefPubMed

37.

Ames PR, Antinolfi I, Scenna G, Gaeta G, Margaglione M, Margarita A (2009) Atherosclerosis in thrombotic primary antiphospholipid syndrome. J Thromb Haemost: JTH 7(4):537–542CrossRefPubMed

38.

Giles I, Khamashta M, D’Cruz D, Cohen H (2012) A new dawn of anticoagulation for patients with antiphospholipid syndrome? Lupus 21(12):1263–1265CrossRefPubMed

39.

Lopez-Pedrera C, Ruiz-Limon P, Aguirre MA, Rodriguez-Ariza A, Cuadrado MJ (2012) Potential use of statins in the treatment of antiphospholipid syndrome. Curr Rheumatol Rep 14(1):87–94CrossRefPubMed

40.

Mok CC, Kwok CL, Ho LY, Chan PT, Yip SF (2011) Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum 63(5):1182–1189CrossRefPubMed

41.

Souza DC, Santo AH, Sato EI (2012) Mortality profile related to systemic lupus erythematosus: a multiple cause-of-death analysis. J Rheumatol 39(3):496–503CrossRefPubMed

42.

Zonana-Nacach A, Camargo-Coronel A, Yanez P, Sanchez L, Jimenez-Balderas FJ, Fraga A (2001) Infections in outpatients with systemic lupus erythematosus: a prospective study. Lupus 10(7):505–510CrossRefPubMed

43.

Kang I, Park SH (2003) Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol 15(5):528–534CrossRefPubMed

44.

Gladman DD, Hussain F, Ibanez D, Urowitz MB (2002) The nature and outcome of infection in systemic lupus erythematosus. Lupus 11(4):234–239CrossRefPubMed

45.

Pryor BD, Bologna SG, Kahl LE (1996) Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum 39(9):1475–1482CrossRefPubMed

46.

Zandman-Goddard G, Shoenfeld Y (2005) Infections and SLE. Autoimmunity 38(7):473–485CrossRefPubMed

Medicine Matters Rheumatology

Abstract